May 27, 2020
InMed Releases CBN Preclinical Results in Glaucoma
May 07, 2020
Sight Sciences Introduces the Next-Generation OMNI® Surgical System for Microinvasive Glaucoma Surgery
Mar 30, 2020
Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology
Mar 18, 2020
Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners
Mar 10, 2020
Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucoma
Dec 09, 2019
Sight Sciences Appoints Erica Rogers to its Board of Directors
Oct 22, 2019
International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI® Surgical System Predicate Device (VISCO360®)
Sep 09, 2019
CorNeat Vision Completes Pre-clinical Phase For Synthetic Cornea and Scleral Patch
Sep 04, 2019
Sight Sciences Raises $56M of Growth Capital to Lead the Development of the Standalone MIGS Market and Procedure-Based Dry Eye Market
Apr 30, 2019
Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System
Mar 14, 2019
Ivantis Announces 24-Month Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial
Mar 14, 2019
Clinical Study Demonstrates Long Term IOP Reduction with the OMNI® Surgical System Predicate Device (TRAB®360) in Micro-Invasive Glaucoma Surgery
Aug 13, 2018
Ivantis Announces FDA Approval for Its Innovative Hydrus® Microstent Device for Minimally Invasive Glaucoma Surgery (MIGS)
Apr 16, 2018
Ivantis Announces Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial
Feb 20, 2018
Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Expected to Reach $912 Million by 2023 - Allied Market Research